For the Inventor, By the Inventor

Enter assignee name

Cambridge, United Kingdom

Astex Therapeutics Limited

USPTO Granted Patents = 123

CIPO Patents = 124

EPO Patents = 67

Trademarks = 9

Forward Citations = 1,103

Loading Chart...

Loading Chart...

400 inventors (with patents filed for the assignee):

Valerio Berdini (40 out of 43 patents)

Gordon Saxty (38 out of 41 patents)

Christopher William Murray (34 out of 52 patents)

4. Gianni Chessari (31 out of 32 patents)

5. Steven Howard (28 out of 36 patents)

6. Alison Jo-Anne Woolford (26 out of 29 patents)

7. Maria Grazia Carr (22 out of 22 patents)

8. Charlotte Mary Griffiths-Jones (20 out of 23 patents)

9. Christopher Norbert Johnson (20 out of 62 patents)

10. Paul Graham Wyatt (19 out of 24 patents)

11. Miles Stuart Congreve (18 out of 94 patents)

12. Andrew James Woodhead (18 out of 22 patents)

13. Ildiko Maria Buck (17 out of 31 patents)

14. Gilbert Besong (17 out of 22 patents)

15. Martyn Frederickson (16 out of 16 patents)

Core Competencies:

Bicyclic Heterocycles

Isoindolinone Inhibitors

NRF2 Activators

FGFR Inhibitors

MDM2-P53 Interaction

Pyrazolyl Quinoxaline Kinase Inhibitors

Combination Therapy

Pharmaceutical Compositions

Naphthyridine Derivatives

Quinoxaline Derivatives

HSP90 Inhibitors

Pteridines

123 patents: Sort by Forward Citations

1. 12202828 - Bicyclic heterocycle compounds and their uses in therapy (2025-01-21),

2. 12091409 - Ether linked triazoles as NRF2 activators (2024-09-17),

3. 12077526 - Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them (2024-09-03),

4. 12071429 - Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity (2024-08-27),

5. 11918576 - Combination of an FGFR inhibitor and a CMET inhibitor (2024-03-05),

6. 11866428 - Bicyclic heterocycle compounds and their uses in therapy (2024-01-09),

7. 11684620 - Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine (2023-06-27),

8. 11643410 - Bicyclic heterocycle compounds and their uses in therapy (2023-05-09),

9. 11603367 - Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them (2023-03-14),

10. 11261171 - Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity (2022-03-01),

11. 11236047 - Combination of isoindolinone derivatives with SGI-110 (2022-02-01),

12. 11225476 - Bicyclic heterocycle compounds and their uses in therapy (2022-01-18),

13. 11059816 - Ether linked triazoles as NRF2 activators (2021-07-13),

14. 10981898 - Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity (2021-04-20),

15. 10898482 - Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine (2021-01-26),

Astex Therapeutics Limited is a British pharmaceutical company specializing in the discovery and development of small-molecule therapeutics for oncology and other diseases. With a focus on innovative drug design and precision medicine, Astex has built a diverse pipeline of potential treatments targeting various cancers and genetic disorders. The company employs cutting-edge technologies and has established collaborations with leading academic institutions and pharmaceutical partners worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

123 Patents

#6 in Cambridge

#134 in United Kingdom

#6,306 in the World

Cambridge, United Kingdom

Astex Therapeutics Limited

Forward Citations = 1,103

400 inventors:

Valerio Berdini (40 out of 43 patents)

Gordon Saxty (38 out of 41 patents)

Christopher William Murray (34 out of 52 patents)

4. Gianni Chessari (31 out of 32 patents)

5. Steven Howard (28 out of 36 patents)

Please report any incorrect information to support@idiyas.com

Loading…